Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer

International Journal of Cancer

Volumn 133, Issue 2, 2013, Pages 346-356

  Heitzer, Ellen ^a   Auer, Martina ^a   Hoffmann, Eva Maria ^a   Pichler, Martin ^a   Gasch, Christin ^b   Ulz, Peter ^a   Lax, Sigurd ^c   Waldispuehl Geigl, Julie ^a   Mauermann, Oliver ^b   Mohan, Sumitra ^a   Pristauz, Gunda ^a   Lackner, Carolin ^a   Höfler, Gerald ^a   Eisner, Florian ^a   Petru, Edgar ^a   Sill, Heinz ^a   Samonigg, Hellmut ^a   Pantel, Klaus ^b   Riethdorf, Sabine ^b   Bauernhofer, Thomas ^a,d   Geigl, Jochen B ^a   Speicher, Michael R ^a   more..

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c General Hospital Graz West   (Austria)

^d LKH Leoben Eisenerz   (Austria)

Author keywords

copy number changes; plasma DNA; predictive and prognostic biomarker; tumor monitoring

Indexed keywords

DNA FRAGMENT;

ANALYTIC METHOD; ARTICLE; BREAST METASTASIS; CANCER PATIENT; CANCER STAGING; CELL COUNT; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA DETERMINATION; FEMALE; HUMAN; HUMAN CELL; MALE; MUTATIONAL ANALYSIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; SEQUENCE ANALYSIS; TUMOR CELL;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DNA, NEOPLASM; FEMALE; GENE DOSAGE; GENES, RAS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; SEQUENCE ANALYSIS, DNA;

EID: 84877806778     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28030     Document Type: Article

References (35)

1. Walther A, Johnstone E, Swanton C, et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009; 9: 489-99.
2. Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977; 37: 646-50.
3. Stroun M, Anker P, Maurice P, et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989; 46: 318-22.
4. Pinzani P, Salvianti F, Zaccara S, et al. Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations. Clin Chim Acta 2010; 412: 2141-5.
5. Schwarzenbach H, Hoon DS, Pantel K,. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11: 426-37.
6. Sidransky D,. Emerging molecular markers of cancer. Nat Rev Cancer 2002; 2: 210-9.
7. van der Vaart M, Pretorius PJ,. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated? Clin Biochem 2010; 43: 26-36.
8. Muller I, Beeger C, Alix-Panabieres C, et al. Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: potential and technical improvements. Clin Chem 2008; 54: 688-96.
9. Schwarzenbach H, Alix-Panabieres C, Muller I, et al. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 2009; 15: 1032-8.
10. Begum S, Brait M, Dasgupta S, et al. An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin Cancer Res 2011; 17: 4494-503.
11. Gormally E, Caboux E, Vineis P, et al. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 2007; 635: 105-17.
12. Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005; 102: 16368-73.
13. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008; 14: 985-90.
14. Diehl F, Schmidt K, Durkee KH, et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology 2008; 135: 489-98.
15. Leary RJ, Kinde I, Diehl F, et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2010; 2: 20ra14.
16. McBride DJ, Orpana AK, Sotiriou C, et al. Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Gene Chromosome Cancer 2010; 49: 1062-9.
17. Nawroz H, Koch W, Anker P, et al. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 1996; 2: 1035-7.
18. Yung TK, Chan KC, Mok TS, et al. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 2009; 15: 2076-84.
19. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-6.
20. Diaz LA, Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486: 537-40.
21. Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012; 4: 136ra68.
22. Dhallan R, Au WC, Mattagajasingh S, et al. Methods to increase the percentage of free fetal DNA recovered from the maternal circulation. JAMA 2004; 291: 1114-9.
23. Lo YM, Chan KC, Sun H, et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med 2010; 2: 61ra91.
24. Riethdorf S, Fritsche H, Muller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007; 13: 920-8.
25. Diehl F, Li M, He Y, et al. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods 2006; 3: 551-9.
26. Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011; 3: 111ra21.
27. Bignell GR, Greenman CD, Davies H, et al. Signatures of mutation and selection in the cancer genome. Nature 2010; 463: 893-8.
28. Kan Z, Jaiswal BS, Stinson J, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010; 466: 869-73.
29. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001; 61: 1659-65.
30. Pinzani P, Salvianti F, Pazzagli M, et al. Circulating nucleic acids in cancer and pregnancy. Methods 2010; 50: 302-7.
31. Umetani N, Kim J, Hiramatsu S, et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem 2006; 52: 1062-9.
32. Wang BG, Huang HY, Chen YC, et al. Increased plasma DNA integrity in cancer patients. Cancer Res 2003; 63: 3966-8.
33. Chan KC, Jiang P, Zheng YW, et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 2013; 59: 211-24.
34. Leary RJ, Sausen M, Kinde I, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 2012; 4: 162ra54.
35. Lo YM, Zhang J, Leung TN, et al. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999; 64: 218-24.